(Q34604646)

3 August 2017

1 reference

14 December 2019

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer (English)

1 reference

hormone-dependent neoplasms

3 August 2017

1 reference

28 September 2019

1 reference

3 April 2019

Steroid 17alpha-monooxygenase

1 reference

28 September 2019

1 reference

13 November 2019

1 reference

1 reference

J E Ang

1

1 reference

3 August 2017

D Olmos

series ordinal

2

1 reference

3 August 2017

J S de Bono

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

17 February 2009

1 reference

British Journal of Cancer

3 August 2017

10 March 2009

6 references

3 April 2019

1 July 2019

28 September 2019

13 November 2019

18 November 2019

14 December 2019

7 references

3 August 2017

3 April 2019

1 July 2019

28 September 2019

13 November 2019

18 November 2019

14 December 2019

100

1 reference

3 August 2017

5

1 reference

3 August 2017

671-675

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604904

3 August 2017

0 references

cites work

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Drug insight: role of the androgen receptor in the development and progression of prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Estimates of the cancer incidence and mortality in Europe in 2006.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Mechanisms underlying the development of androgen-independent prostate cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Overview of dehydroepiandrosterone biosynthesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Molecular determinants of resistance to antiandrogen therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2653756

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

The regulation of 17,20 lyase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

Prostate cancer: moving forward by reinventing the wheel...but this time it is round

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604904

Treating prostate cancer: a rationale for targeting local oestrogens

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19223900

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19223900

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19223900

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6604904

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference